

1 Post-Market Surveillance of Six COVID-19 Point-of-Care Tests Using

2 Pre-Omicron and Omicron SARS-CoV-2 Variants

3 Running Title: PMS of COVID-19 POCT using SARS-CoV-2 Variants

4
5 **Hannah M. Exner^a, Branden S. J. Gregorchuk^a, AC-Green Castor^a, Leandro Crisostomo^a, Kurt**
6 **Kolsun^b, Shayna Giesbrecht^b, Kerry Dust^c, David Alexander^c, Ayooluwa Bolaji^c, Zoe Quill^a,**
7 **Breanne M. Head^a, Adrienne F. A. Meyers^d, Paul Sandstrom^{a,e}, Michael G. Becker^{a,b,*}**

8 ^aJC Wilt Infectious Diseases Research Centre, National Microbiology Laboratory Branch, Public
9 Health Agency of Canada, Winnipeg, Manitoba, Canada

10 ^bDepartment of Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada

11 ^cCadham Provincial Laboratory, Winnipeg, Manitoba, Canada

12 ^dOffice of Population and Public Health, Indigenous Services Canada, Ottawa, Ontario, Canada

13 ^eDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg,
14 Manitoba, Canada

15
16 *Address correspondence to Michael Becker, Michael.Glen.Becker@phac-aspc.gc.ca

38 **ABSTRACT**

39 Post-market surveillance of test performance is a critical function of public health
40 agencies and clinical researchers that ensures diagnostics maintain performance characteristics
41 following their regulatory approval. Changes in product quality, manufacturing processes over
42 time, or the evolution of new variants may impact product quality. During the COVID-19
43 pandemic, a plethora of point-of-care tests (POCTs) were released onto the Canadian market.
44 This study evaluated the performance characteristics of several of the most widely-distributed
45 POCTs in Canada, including four rapid antigen tests (Abbott Panbio, BTNX Rapid Response, SD
46 Biosensor, Quidel QuickVue) and two molecular tests (Abbott ID NOW, Lucira Check IT). All tests
47 were challenged with 149 SARS-CoV-2 clinical positives, including multiple variants up to and
48 including Omicron XBB.1.5, as well as 29 clinical negatives. Results were stratified based on
49 whether the isolate was Omicron or pre-Omicron as well as by RT-qPCR Ct value. The test
50 performance of each POCT was consistent with the manufacturers' claims and showed no
51 significant decline in clinical performance against any of the variants tested. These findings
52 provide continued confidence in the results of these POCTs as they continue to be used to
53 support decentralized COVID-19 testing. This work demonstrates the essential role of post-
54 market surveillance in ensuring reliability in diagnostic tools.

55

56

57

58

59

60 INTRODUCTION

61 During the COVID-19 pandemic, it became clear that an effective public health response
62 required rapid and widespread testing for SARS-CoV-2. Although testing initially relied on
63 laboratory-based reverse transcriptase quantitative PCR (RT-qPCR), decentralized testing quickly
64 became the preferred screening method (1, 2) facilitated through the use of point-of-care tests
65 (POCTs). This shift was accelerated following the emergence of the highly transmissible Omicron
66 variant (Pango lineage B.1.1.529) in December 2021 (3-5) causing unprecedented testing
67 demand that overwhelmed centralized testing facilities (4-6). As of August 2023, 55 POCTs have
68 been authorized for use in Canada through the *“Interim order respecting the importation and*
69 *sale of medical devices for use in relation to COVID-19”* (7). These devices can be broadly
70 categorized into two groups: molecular tests and rapid antigen detection tests (RADTs).
71 Molecular POCTs detect the presence of SARS-CoV-2-specific nucleic acid sequences through PCR
72 or isothermic amplification techniques such as loop-mediated isothermal amplification (LAMP)
73 (1, 8, 9). Molecular tests generally provide a high level of sensitivity and may detect viral RNA
74 weeks after infection (9-11). In comparison, RADTs detect SARS-CoV-2 surface proteins with
75 decreased sensitivity, particularly when considering asymptomatic cases with lower viral loads
76 (12-14).

77 Post-market surveillance monitors the performance of POCTs following
78 commercialization and distribution as well as provides independent investigations that assess the
79 manufacturers’ claims regarding test efficacy in real-world settings (15). Ongoing monitoring
80 becomes exceedingly important for POCTs as few quality controls are in place compared to

81 clinical testing performed in centralized test facilities. Test performance may also deviate over
82 time due to changes in manufacturing materials or processes (16, 17), or through viral evolution
83 of test targets. For molecular POCTs, test performance may be impacted by base substitutions at
84 the primer binding sites, which can often be predicted *in silico* (18). RADT performance may also
85 be impacted by mutations within target proteins, however, predicting this computationally is
86 more challenging as it is influenced by protein 3D structure. Therefore, post-market surveillance
87 of RADTs relies more heavily on experimentation.

88 Initial studies evaluating the performance of various RADTs found reduced impaired
89 detection of Omicron variants compared to previously circulating strains (19-21). For example,
90 Osterman et al. reported that multiple RADTs tested had 101-fold lower sensitivity against
91 Omicron BA.1 compared to Delta (21). Although this study may raise concerns surrounding the
92 continued use of these RADTs, multiple subsequent studies demonstrated equivalent sensitivity
93 regardless of variant (22-24). Together, this emphasizes the need to disseminate negative test
94 results in post-market surveillance studies.

95 Due to the variety of POCTs available globally, tests evaluated in published research often
96 have little to no overlap with the POCTs widely distributed in Canada. Although manufacturers
97 may provide post-market surveillance data regarding performance, these may be based heavily
98 on *in silico* analyses and experimental results may differ (25). Therefore, there is a need for
99 regulatory bodies, clinicians, and public health officials to conduct ongoing aftermarket
100 evaluations and to effectively communicate the results to POCT users. Accordingly, the aim of
101 this post-market surveillance study was to assess the analytical performance of six widely

102 distributed POCTs and to determine if there were differences in the detection of pre-Omicron
103 and Omicron variants.

104 **MATERIALS AND METHODS**

105 SARS-CoV-2 positive and negative patient samples were used to determine the sensitivity,
106 specificity, and experimental limit of detection (LoD) of each of the COVID-19 POCTs. Clinical
107 samples, reference cycle thresholds (Ct), and lineage data were provided by Cadham Provincial
108 Laboratory (CPL; Manitoba, Canada). Reference Ct values were characterized on remnant
109 universal transport media (UTM) from 149 SARS-CoV-2 positive and 29 negative nasopharyngeal
110 swabs using the Roche 6800 Cobas SARS-CoV-2 test targeting the Open Reading Frame 1a and
111 Envelope genes. Samples were then categorized based on lineage into pre-Omicron (Alpha
112 [B.1.1.7], Delta [B.1.617.2]) or Omicron (BA.1, BA.2, BA.4, BA.5, or XBB.1.5) groups (Table 1). For
113 samples for which lineage data was not available (collected before routine sequencing), lineage
114 was predicted based on the sampling date. No ethics were required under Article 2.4 and Article
115 2.5 of the *Tri-Council Policy Statement Ethical Conduct for Research Involving Humans* (26) as
116 these were remnant clinical specimens used for assay validation. To minimize sample
117 degradation, each sample was limited to a maximum of two freeze-thaw cycles.

118

119

120

121 **TABLE 1.** Lineage of SARS-CoV-2 positive clinical samples used in the study.

SARS-CoV-2 Lineage	Number of Samples
Alpha	40
Delta/Kappa	15
Omicron BA.1	25
Omicron BA.2	15
Omicron BA.4	10
Omicron BA.5	23
Omicron XBB.1.5	21

122 Six Health Canada-approved COVID-19 POCTs were evaluated in this study; four RADTs
123 including the BTNX Rapid Response® COVID-19 Antigen Rapid Test (BTNX Inc., Canada), the
124 Abbott Panbio™ COVID-19 Ag Rapid Test Device (Abbott Rapid Diagnostics Jena GmbH, Germany),
125 the SD Biosensor COVID-19 Ag Test (SD Biosensor Inc., South Korea) and the Quidel QuickVue®
126 At-Home OTC COVID-19 Test (Quidel Corporation, United States); as well as two LAMP-based
127 molecular tests: the Abbott ID NOW™ COVID-19 Assay (Abbott Diagnostics Scarborough, Inc.,
128 United States) and the Lucira™ Check IT COVID-19 Test Kit (Lucira Health, Inc., United States).

129 For each POCT, 10 µL of remnant UTM was transferred directly into the assay buffer and
130 subsequently mixed with the manufacturer-provided swab. Each test was then performed
131 according to the manufacturer's instructions. For RADT results that required visual
132 interpretation, test strips were read independently by three technicians and the consensus was
133 reported. If necessary, invalid tests were repeated until a positive or negative result was
134 encountered.

135 Data were analyzed using R version 4.2.1 software. Sample Ct values were adjusted to
136 account for the quantity of virus input into the device corresponding to the concentration when
137 eluted into a 3 mL volume. Continuous variables such as Ct are represented as medians and

138 interquartile ranges (IQR). Categorical variables, such as sensitivity and specificity, are reported
139 as percentages with 95% confidence intervals (95% CI) calculated using the Wilson score method.
140 Sensitivity was also determined for each POCT when samples were stratified based on a Ct of \leq
141 30 and > 30 , i.e., the acceptable LoD outlined by the World Health Organization (WHO) for RADTs
142 (27) and the cut-off typically used in clinical settings and other evaluations (2, 16, 28). For each
143 POCT, the overall and stratified sensitivity values were compared between the pre-Omicron and
144 Omicron groups using a two-tailed Fisher's Exact Test with an α of 0.05.

145 Next, based on the guidelines recommended by the Clinical & Laboratory Standards
146 Institute (29), a probit model was constructed for each assay to determine the 95% LoD,
147 representing the estimated concentration at which 95% of positive samples are successfully
148 identified. The 95% CI for each LoD was calculated using the Wald method, then the LoDs were
149 compared between Pre-Omicron and Omicron to determine if the analytical sensitivity of each
150 POCT differed by variant.

151 **RESULTS**

152 *Performance Characteristics of POCTs with Pre-Omicron and Omicron Variants*

153 A total of 149 SARS-CoV-2 clinical positives with a median Ct value of 30.2 (IQR 26.8–33.8)
154 and 29 SARS-CoV-2 clinical negatives were tested using all six POCTs. Of the positive samples, 94
155 were determined to be Omicron subvariants (median Ct value 29.7; IQR 27.1–33.5) and the
156 remaining 55 were identified as pre-Omicron (median Ct value 30.0; IQR 26.0–34.4). No false

157 positives were recorded resulting in a specificity of 100% (95% CI, 88–100%) across all tests. Three
158 invalid results were obtained during the study: two with the ID NOW and one with the Check IT.

159 Overall sensitivity of RADTs ranged from 46-65% compared to 86-98.9% for molecular
160 tests (Table 2). For all tests, sensitivity was similar between Omicron compared to pre-Omicron
161 samples when analyzing all Ct values together. Similarly, when stratifying test results by Ct for all
162 tests, no significant difference in sensitivity was observed between pre-Omicron and Omicron
163 samples with high viral loads (i.e., Ct \leq 30; Table 2). At low viral loads (i.e., Ct $>$ 30), significant
164 differences in ID NOW ($p = 0.021$) and QuickVue ($p = 0.028$) sensitivity was observed between
165 pre-Omicron and Omicron variants.

166 *Limit of Detection Analysis of POCTs With All Variants*

167 Probit regression analyses was performed using data from all 149 SARS-CoV-2 clinical
168 specimens to determine the 95% LoD of each test (Fig. 1). The molecular POCTs, the ID NOW and
169 Check IT, had 95% LoDs of 34.7 and 39.3 Ct values, respectively, highlighting their ability to detect
170 low quantities of virus. RADTs had 95% LoDs ranging between 25.0 to 28.4 (Table A1).

171

172

173

174

175 **Table 2.** Performance characteristics of six COVID-19 point-of-care tests with Pre-Omicron and
 176 Omicron samples


Test	Ct	Pre-Omicron			Omicron			P-value
		n	Sensitivity (%)	95% CI	n	Sensitivity (%)	95% CI	
Molecular Tests								
ID NOW	Overall	55	86	(74–92.4)	94	94.7	(88–97.7)	0.072
	≤30	30	100	(89–100)	41	100	(91.4–100)	1.000
	>30	25	68	(48–83)	53	90.6	(80–95.9)	0.021*
Check IT	Overall	55	98.2	(90.4–99.7)	94	98.9	(94.2–99.8)	1.000
	≤30	30	100	(91.4–100)	41	100	(89–100)	1.000
	>30	25	98.1	(90.1–99.7)	53	99.3	(81–99.3)	0.541
Rapid Antigen Detection Tests								
Rapid Response	Overall	55	64	(50–75)	94	65	(55–74)	1.000
	≤30	30	96.7	(83–99.4)	41	97.6	(87–99.6)	1.000
	>30	25	24	(12–43)	53	40	(28–53)	0.210
Panbio	Overall	55	51	(38–64)	94	49	(39–59)	0.866
	≤30	30	90.2	(78–96.1)	41	83	(66–92.7)	0.479
	>30	25	17	(9.2–29)	53	12	(4.2–30)	0.742
QuickVue	Overall	55	49	(36–62)	94	55	(45–65)	0.499
	≤30	30	87	(70–94.7)	41	92.7	(81–97.5)	0.446
	>30	25	4.0	(0.7–20)	53	26	(16–40)	0.028*
Biosensor	Overall	55	60	(47–72)	94	47	(37–57)	0.130
	≤30	30	93.3	(79–98.2)	41	85	(72–93.1)	0.453
	>30	25	20	(8.9–39)	53	17	(9.2–29)	0.759

177 CI: Confidence Interval; Ct: Cycle Threshold; n: number of SARS-CoV-2 positive samples tested; *:
 178 significant at P<0.05 for difference in POCT sensitivity between pre-Omicron and Omicron variants using
 179 Fisher’s exact test.

180

181

182




183 **FIG 1.** Probit regression analysis showing the 95% limit of detection of six SARS-CoV-2 point-of-
184 care tests based on testing outcomes of 149 positive SARS-CoV-2 clinical samples. The cycle
185 threshold of the sample, determined using the RT-qPCR reference standard test result, is plotted
186 against a positive (1) or negative (0) test outcome. The horizontal dashed line indicates the 95%
187 probability of a positive test result while the vertical dashed lines show the 95% limit of
188 detection of each test with shaded areas representing their 95% confidence interval.

189 Limit of Detection Analysis of POCTs For Pre-Omicron and Omicron Variants

190 A probit regression model was used to assess if the limit of detection of each test differed
191 when stratified by variant (pre-Omicron vs Omicron). The 95% LoDs of all the POCTs were similar,
192 regardless of the variant, as demonstrated by the sizeable overlap between their confidence
193 intervals (Fig. 2). Due to a poor model fit from lack of false negative results, it was not possible

194 to determine the 95% LoD of the Check IT for the pre-Omicron and Omicron variant samples,
195 suggesting that performance of this molecular test is on par with the reference test.



196

197 **FIG 2.** *Probit regression analysis with the 95% limit of detection of five SARS-CoV-2 point-of-care*
198 *tests grouped by variant, based on testing outcomes of 149 positive SARS-CoV-2 clinical*
199 *samples. Results for pre-Omicron and Omicron samples are represented in blue and red,*
200 *respectively. The cycle threshold of the sample, determined by the RT-qPCR reference standard*
201 *test result, is plotted against a positive (1) or negative (0) outcome of the test. The horizontal*
202 *dashed line indicates the 95% probability of a positive test result while the vertical dashed lines*
203 *show the 95% limit of detection of each test with shaded areas representing their 95%*
204 *confidence interval.*

205 **DISCUSSION**

206 POCTs have been central to the COVID-19 pandemic response, particularly following the
207 appearance of the Omicron variant in late 2021 (2, 3). As new variants emerge, it is important to
208 monitor the performance of POCTs to ensure that test results continue to be reliable.
209 Consequently, the purpose of this study was to evaluate six widely-distributed Health Canada-
210 approved POCTs using COVID-19 clinical samples incorporating pre-Omicron and Omicron
211 variants (Alpha to XBB.1.5) to determine if test characteristics differed over time. Overall, our
212 assessment revealed consistent and reliable performance across the variants tested, affirming
213 manufacturer’s claims that there is no notable decrease in clinical efficacy. The molecular tests,
214 ID NOW and Check IT, demonstrated the highest sensitivity, and can provide RT-qPCR level
215 quality in settings where centralized testing is unavailable (30).

216 To our knowledge, only two studies, conducted by Stokes et al. (31, 32), have assessed
217 the performance characteristics of the ID NOW in detecting both pre-Omicron and Omicron

218 variants. Per Stokes et al. (31, 32), for symptomatic patients, the ID NOW demonstrated improved
219 sensitivity against Omicron (91.6–96.0%) compared to pre-Omicron (90.0–92.5%). This aligns
220 with the significant increase in test sensitivity against high Ct clinical Omicron samples noted in
221 this study. Potential explanations for this finding may be attributed to various factors including
222 changes in testing procedures over time, patient infection stage, or sample storage and quality.
223 Studies have also reported decreased ID NOW performance with higher Ct samples (33-35). In
224 contrast to traditional RT-qPCR, the ID NOW employs LAMP-based technology that targets a large
225 RNA fragment (>1 kb). Therefore, the device may exhibit reduced sensitivity with fragmented
226 samples from long-term storage, which may be a confounding factor in clinical LAMP validation
227 studies. Additionally, the ID NOW targets RNA-dependant RNA polymerase, an uncommon target
228 among COVID-19 POCTs and RT-qPCR assays. This feature may cause the ID NOW to be affected
229 uniquely by variant mutations as compared to other tests, and the Ct value from the reference
230 assay (targeting N2) may not accurately reflect the abundance of target RNA in each sample.

231 The Check IT has only been independently evaluated in one other publication to date. In
232 a study by Zahavi et al. (8), the device exhibited a sensitivity of 91.1% using samples collected
233 before the emergence of Omicron. This is consistent with the high sensitivity of the Check IT
234 when using both pre-Omicron and Omicron variants observed in this study, with the LoD
235 comparable to that of laboratory-developed qRT-PCR tests.

236 Using the WHO guidelines for RADT evaluation and clinical relevance (27), at high viral
237 loads (Ct ≤ 30) all RADTs met the criteria for acceptable clinical sensitivity (> 80%). In agreement
238 with previous reports and manufacturer claims, test sensitivity of RADTs decreased markedly at

239 low viral loads (Ct > 30) regardless of variant. It is important to note that comparing LoDs and
240 sensitivity across studies, especially for RADTs, is often challenging due to differences in
241 experimental design. For example, reference Ct values can differ greatly based on methodology
242 and gene target. Recently, media reported on possible issues in the design of the BTNX validation
243 studies used for regulatory approval (36); however, this study corroborates manufacturer claims
244 and has identified no appreciable differences in analytical test performance between the BTNX
245 and the other RADTs investigated in this study.

246 A meta-analysis by Mohammadie et al. (37) on RADT performance revealed a pooled
247 sensitivity of 67% and a non-significant reduction in overall RADT sensitivity against Omicron.
248 While these general trends provide valuable insights into overall RADT performance, the diversity
249 of targets needs to be considered. Although as a group RADTs demonstrate compatibility with
250 emerging variants, each test recognizes unique viral epitopes and should also be investigated
251 individually.

252 The QuickVue RADT showed significantly improved sensitivity against low viral load
253 Omicron samples, consistent with findings by Sugiharto et al. (24); however, work by Rao et al.
254 (38) showed no change in QuickVue sensitivity against Omicron variants. All other RADTs
255 evaluated in this study showed no significant change in test performance against Omicron
256 variants. Previous studies evaluating RADTs have consistently reported similar or reduced clinical
257 sensitivity with Omicron as compared to early pandemic variants (21, 37, 39). For example,
258 multiple studies investigating the Abbott Panbio using cultured virus (40) and clinical samples
259 (23, 41) have shown no sensitivity loss against Omicron. Alternatively, work by Bekliz al. (19)

260 reported a significant reduction in Panbio sensitivity with Omicron BA.1 compared to Delta.
261 Biosensor demonstrated comparable performance with cultured Omicron variants (40, 42), but
262 in other studies exhibited reduced clinical sensitivity (19, 20). To our knowledge, this is the first
263 study investigating the sensitivity of the BTNX Rapid Response against multiple SARS-CoV-2
264 variants including Omicron.

265 A limitation of this study is the use of anonymized remnant clinical samples instead of
266 clinical patient swabs. The use of clinical swabs was not feasible as multiple variants investigated
267 in this study are no longer circulating and this study required a large number of paired samples
268 to evaluate multiple technologies. Due to the anonymization of samples used in this study, we
269 were not able to incorporate information that may affect test sensitivity or specificity, such as
270 vaccination status or patient clinical presentation, into our analyses (13, 14, 39).

271 Unlike many studies that primarily focused on comparing BA.1 exclusively with the Delta
272 variant, our research included a representative range of both pre-Omicron and Omicron
273 subvariants (Alpha to XBB.1.5). Considering both the overall sensitivity and limit of detection, we
274 observed no decline in test performance against Omicron variants; however, it is important to
275 continue to evaluate these parameters as new variants emerge. Sustained post-market
276 surveillance efforts are required to proactively identify issues that could impact decentralized
277 testing for COVID-19.

278

279

280 **ETHICS APPROVAL**

281 No ethics were required under Article 2.4 and Article 2.5 of the *Tri-Council Policy*
282 *Statement Ethical Conduct for Research Involving Humans* (26) since remnant clinical specimens
283 were used for the purpose of quality assurance.

284 **FUNDING**

285 This research was funded by the Public Health Agency of Canada.

286 **CONFLICTS OF INTEREST**

287 The authors declare no conflict of interest.

288

289

290

291

292

293

294

295

296 **SUPPLEMENTAL MATERIAL**

297 **Table A1.** Probit regression calculated 95% Limit of Detection of six COVID-19 point-of-care tests
 298 based on 149 SARS-CoV-2 positive clinical samples.

Test	Predicted 95% LoD (Ct) 95% CI ¹					
	All (n=149)		Pre-omicron (n=54)		Omicron (n=95)	
Molecular Tests						
ID NOW	34.7	(33.1, 36.4)	34.6	(32.6, 36.6)	35.8	(33.4, 38.2)
Check IT	39.3	(37.2, 41.4)	N/A ²		38.7	(35.6, 41.8)
Rapid Antigen Tests						
Panbio	26.3	(24.9, 27.6)	25.9	(23.8, 27.9)	26.6	(24.9, 28.4)
Rapid Response	28.4	(27.0, 29.7)	28.7	(26.8, 30.7)	28.2	(26.4, 30.1)
QuickVue	26.6	(25.2, 28.0)	25.4	(23.1, 27.6)	27.7	(26.1, 29.3)
Biosensor	25.0	(23.2, 26.8)	26.1	(23.4, 28.8)	24.4	(21.9, 26.9)

299 ¹95% Wald confidence intervals; ²N/A since insufficient data, n - number of SARS-CoV-2 positive samples.

300 **REFERENCES**

- 301 1. Zhang Y, Garner R, Salehi S, Rocca M, Duncan D. 2022. Molecular and antigen tests, and sample
 302 types for diagnosis of COVID-19: a review. *Future Virol* 17:675-85.
- 303 2. Buchta C, Gorzer I, Chiba P, Camp JV, Holzmann H, Puchhammer-Stockl E, Mayerhofer M, Muller
 304 MM, Aberle SW. 2021. Variability of cycle threshold values in an external quality assessment
 305 scheme for detection of the SARS-CoV-2 virus genome by RT-PCR. *Clin Chem Lab Med* 59:987-
 306 994.
- 307 3. Vogel L. 2022. An early look at Omicron. *CMAJ* 194:E58.
- 308 4. Temsah MH, Alenezi S, Alarabi M, Aljamaan F, Alhasan K, Assiri R, Bassrawi R, Alshahrani F,
 309 Alhaboob A, Alaraj A, Alharbi NS, Arabiaah A, Halwani R, Jamal A, Abdulmajeed N, Alfarra L,
 310 Almarshdali W, Al-Eyadhy A, AlZamil F, Alsubaie S, Barry M, Memish ZA, Al-Tawfiq JA. 2022.
 311 Healthcare Workers' SARS-CoV-2 Omicron Variant Uncertainty-Related Stress, Resilience, and
 312 Coping Strategies during the First Week of the World Health Organization's Alert. *Int J Environ*
 313 *Res Public Health* 19.
- 314 5. Singhal T. 2022. The Emergence of Omicron: Challenging Times Are Here Again! *Indian J Pediatr*
 315 89:490-496.
- 316 6. Mahase E. 2021. Covid-19: Hospital admission 50-70% less likely with omicron than delta, but
 317 transmission a major concern. *BMJ* 375:n3151.
- 318 7. Government of Canada. 2023. Interim order respecting the importation and sale of medical
 319 devices for use in relation to COVID-19. [https://www.canada.ca/en/health-
 320 canada/services/drugs-health-products/drug-products/announcements/interim-order-
 321 importation-sale-medical-devices-covid-19.html](https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/interim-order-importation-sale-medical-devices-covid-19.html). Accessed 2023-09-04.
- 322 8. Zahavi M, Rohana H, Azrad M, Shinberg B, Peretz A. 2022. Rapid SARS-CoV-2 Detection Using the
 323 Lucira Check It COVID-19 Test Kit. *Diagnostics (Basel)* 12.
- 324 9. Chu VT, Schwartz NG, Donnelly MAP, Chuey MR, Soto R, Yousaf AR, Schmitt-Matzen EN, Sleweon
 325 S, Ruffin J, Thornburg N, Harcourt JL, Tamin A, Kim G, Folster JM, Hughes LJ, Tong S, Stringer G,

- 326 Albanese BA, Totten SE, Hudziec MM, Matzinger SR, Dietrich EA, Sheldon SW, Stous S, McDonald
327 EC, Austin B, Beatty ME, Staples JE, Killerby ME, Hsu CH, Tate JE, Kirking HL, Matanock A, Team C-
328 HT. 2022. Comparison of Home Antigen Testing With RT-PCR and Viral Culture During the Course
329 of SARS-CoV-2 Infection. *JAMA Intern Med* 182:701-709.
- 330 10. Leitao IC, Calil PT, Galliez RM, Moreira FRR, Mariani D, Castineiras ACP, da Silva GPD, Maia RA,
331 Correa IA, Monteiro FLL, de Souza MRM, Goncalves CCA, Higa LM, de Jesus Ribeiro L, Fonseca
332 VWP, Bastos VC, Voloch CM, Faffe DS, da Costa Ferreira O, Jr., Tanuri A, Castineiras T, da Costa LJ,
333 on the behalf of the U-CW. 2021. Prolonged SARS-CoV-2 Positivity in Immunocompetent
334 Patients: Virus Isolation, Genomic Integrity, and Transmission Risk. *Microbiol Spectr* 9:e0085521.
- 335 11. Bar-On YM, Flamholz A, Phillips R, Milo R. 2020. SARS-CoV-2 (COVID-19) by the numbers. *Elife* 9.
- 336 12. Dinnes J, Sharma P, Berhane S, van Wyk SS, Nyaaba N, Domen J, Taylor M, Cunningham J,
337 Davenport C, Dittrich S, Emperador D, Hooft L, Leeflang MM, McInnes MD, Spijker R, Verbakel JY,
338 Takwoingi Y, Taylor-Phillips S, Van den Bruel A, Deeks JJ, Cochrane C-DTAG. 2022. Rapid, point-of-
339 care antigen tests for diagnosis of SARS-CoV-2 infection. *Cochrane Database Syst Rev*
340 7:CD013705.
- 341 13. Parvu V, Gary DS, Mann J, Lin YC, Mills D, Cooper L, Andrews JC, Manabe YC, Pekosz A, Cooper
342 CK. 2021. Factors that Influence the Reported Sensitivity of Rapid Antigen Testing for SARS-CoV-
343 2. *Front Microbiol* 12:714242.
- 344 14. Robinson ML, Mirza A, Gallagher N, Boudreau A, Garcia Jacinto L, Yu T, Norton J, Luo CH, Conte
345 A, Zhou R, Kafka K, Hardick J, McManus DD, Gibson LL, Pekosz A, Mostafa HH, Manabe YC. 2022.
346 Limitations of Molecular and Antigen Test Performance for SARS-CoV-2 in Symptomatic and
347 Asymptomatic COVID-19 Contacts. *J Clin Microbiol* 60:e0018722.
- 348 15. Patriquin G, Davidson RJ, Hatchette TF, Head BM, Mejia E, Becker MG, Meyers A, Sandstrom P,
349 Hatchette J, Block A, Smith N, Ross J, LeBlanc JJ. 2021. Generation of False-Positive SARS-CoV-2
350 Antigen Results with Testing Conditions outside Manufacturer Recommendations: A Scientific
351 Approach to Pandemic Misinformation. *Microbiol Spectr* 9:e0068321.
- 352 16. Li X, Tam AR, Chu WM, Chan WM, Ip JD, Chu AW, Abdullah SMU, Yip CC, Chan KH, Wong SS,
353 Cheng VC, Yuen KY, Hung IF, To KK. 2022. Risk Factors for Slow Viral Decline in COVID-19 Patients
354 during the 2022 Omicron Wave. *Viruses* 14.
- 355 17. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, Subramoney K, Makatini Z,
356 Moyo S, Amoako DG, Baxter C, Althaus CL, Anyaneji UJ, Kekana D, Viana R, Giandhari J, Lessells
357 RJ, Maponga T, Maruapula D, Choga W, Matshaba M, Mbulawa MB, Msomi N, consortium N-S,
358 Naidoo Y, Pillay S, Sanko TJ, San JE, Scott L, Singh L, Magini NA, Smith-Lawrence P, Stevens W, Dor
359 G, Tshiabuila D, Wolter N, Preiser W, Treurnicht FK, Venter M, Chiloane G, McIntyre C, O'Toole A,
360 Ruis C, Peacock TP, Roemer C, Kosakovsky Pond SL, Williamson C, Pybus OG, Bhiman JN, Glass A,
361 et al. 2022. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. *Nat Med*
362 28:1785-1790.
- 363 18. U.S. Food & Drug Administration. 23-09-28 2023. SARS-CoV-2 Viral Mutations: Impact on
364 COVID-19 Tests. [https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-
365 devices/sars-cov-2-viral-mutations-impact-covid-19-tests](https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests). Accessed 2023-11-05.
- 366 19. Bekliz M, Adea K, Puhach O, Perez-Rodriguez F, Marques Melancia S, Baggio S, Corvaglia AR,
367 Jacquerioz F, Alvarez C, Essaidi-Laziosi M, Escadafal C, Kaiser L, Eckerle I. 2022. Analytical
368 Sensitivity of Eight Different SARS-CoV-2 Antigen-Detecting Rapid Tests for Omicron-BA.1 Variant.
369 *Microbiol Spectr* 10:e0085322.
- 370 20. Bayart JL, Degosserie J, Favresse J, Gillot C, Didembourg M, Djokoto HP, Verbelen V, Rousset G,
371 Maschietto C, Mullier F, Dogne JM, Douxfils J. 2022. Analytical Sensitivity of Six SARS-CoV-2 Rapid
372 Antigen Tests for Omicron versus Delta Variant. *Viruses* 14.

- 373 21. Osterman A, Badell I, Basara E, Stern M, Kriesel F, Eleteby M, Oztan GN, Huber M, Autenrieth H,
374 Knabe R, Spath PM, Muenchhoff M, Graf A, Krebs S, Blum H, Durner J, Czibere L, Dachert C,
375 Kaderali L, Baldauf HM, Keppler OT. 2022. Impaired detection of omicron by SARS-CoV-2 rapid
376 antigen tests. *Med Microbiol Immunol* 211:105-117.
- 377 22. Gurgeon A, Soulier A, Audureau E, Khouider S, Galbin A, Langlois C, Bouvier-Alias M, Rodriguez
378 C, Chevaliez S, Pawlotsky JM, Fourati S. 2022. Performance of 22 Rapid Lateral Flow Tests for
379 SARS-CoV-2 Antigen Detection and Influence of "Variants of Concern": Implications for Clinical
380 Use. *Microbiol Spectr* 10:e0115722.
- 381 23. de Michelena P, Torres I, Ramos-Garcia A, Gozalbes V, Ruiz N, Sanmartin A, Botija P, Poujois S,
382 Huntley D, Albert E, Navarro D. 2022. Real-life performance of a COVID-19 rapid antigen
383 detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the
384 Omicron variant. *J Infect* 84:e64-e66.
- 385 24. Sugiharto VA, Gatrell SK, Chen HW, Blazek GR, Cherry AM, Schilling M. 2023. Performance
386 Evaluation of Five Rapid At-Home COVID-19 Antigen Tests against the Omicron Variant. *Microbiol*
387 *Spectr* 11:e0228622.
- 388 25. Badnjevic A, Pokvic LG, Deumic A, Becirovic LS. 2022. Post-market surveillance of medical
389 devices: A review. *Technol Health Care* 30:1315-1329.
- 390 26. Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of
391 Canada, and Social Sciences and Humanities Research Council of Canada. 2022. Tri-Council Policy
392 Statement: Ethical Conduct for Research Involving Humans.
- 393 27. Organization WH. 2020. Target product profiles for priority diagnostics to support response to
394 the COVID-19 pandemic v.1.0.
- 395 28. Zacharioudakis IM, Prasad PJ, Zervou FN, Basu A, Inglima K, Weisenberg SA, Aguero-Rosenfeld
396 ME. 2021. Association of SARS-CoV-2 Genomic Load with Outcomes in Patients with COVID-19.
397 *Ann Am Thorac Soc* 18:900-903.
- 398 29. Clinical and Laboratory Standards Institute. 2023. Evaluation of Qualitative, Binary Output
399 Examination Performance. Clinical and Laboratory Standards Institute,
- 400 30. Health Canada. 2021. Pan-Canadian COVID-19 Testing and Screening Guidance: Technical
401 guidance and implementation plan.
- 402 31. Stokes W, Berenger BM, Singh T, Adeghe I, Schneider A, Portnoy D, King T, Scott B, Pabbaraju K,
403 Shokoples S, Wong AA, Gill K, Turnbull L, Hu J, Tipples G. 2021. Acceptable performance of the
404 Abbott ID NOW among symptomatic individuals with confirmed COVID-19. *J Med Microbiol* 70.
- 405 32. Stokes W, Venner AA, Buss E, Tipples G, Berenger BM. 2023. Evaluation of the ID NOW among
406 symptomatic individuals during the Omicron wave. *J Med Microbiol* 72.
- 407 33. Basu A, Zinger T, Inglima K, Woo KM, Atie O, Yurasits L, See B, Aguero-Rosenfeld ME. 2020.
408 Performance of Abbott ID Now COVID-19 Rapid Nucleic Acid Amplification Test Using
409 Nasopharyngeal Swabs Transported in Viral Transport Media and Dry Nasal Swabs in a New York
410 City Academic Institution. *J Clin Microbiol* 58.
- 411 34. Smithgall MC, Scherberkova I, Whittier S, Green DA. 2020. Comparison of Cepheid Xpert Xpress
412 and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2. *J Clin Virol*
413 128:104428.
- 414 35. Mitchell SL, George KS. 2020. Evaluation of the COVID19 ID NOW EUA assay. *J Clin Virol*
415 128:104429.
- 416 36. Sonntag P. 23-12-22 2023. COVID test supplier received billions in pandemic contracts after
417 submitting edited results, *on Global News*, a division of Corus Entertainment Inc.
418 <https://globalnews.ca/news/10183219/covid-test-supplier-canada/>. Accessed 23-12-22.

- 419 37. Mohammadie ZE, Akhlaghi S, Samaeinasab S, Shaterzadeh-Bojd S, Jamialahmadi T, Sahebkar A.
420 2023. Clinical performance of rapid antigen tests in comparison to RT-PCR for SARS-COV-2
421 diagnosis in Omicron variant: A systematic review and meta-analysis. *Rev Med Virol* 33:e2428.
- 422 38. Rao A, Westbrook A, Bassit L, Parsons R, Fitts E, Greenleaf M, McLendon K, Sullivan JA, O'Sick W,
423 Baugh T, Bowers HB, Frank F, Wang E, Le M, Frediani J, Roychoudhury P, Greninger AL, Jerris R,
424 Pollock NR, Ortlund EA, Roback JD, Lam WA, Piantadosi A. 2023. Sensitivity of rapid antigen tests
425 against SARS-CoV-2 Omicron and Delta variants. *J Clin Microbiol* doi:10.1128/jcm.00138-
426 23:e0013823.
- 427 39. Krenn F, Dachert C, Badell I, Lupoli G, Oztan GN, Feng T, Schneider N, Huber M, Both H, Spath
428 PM, Muenchhoff M, Graf A, Krebs S, Blum H, Durner J, Czibere L, Kaderali L, Keppler OT, Baldauf
429 HM, Osterman A. 2023. Ten rapid antigen tests for SARS-CoV-2 widely differ in their ability to
430 detect Omicron-BA.4 and -BA.5. *Med Microbiol Immunol* 212:323-337.
- 431 40. Mackenzie C, Batty M, Papadakis G, Stevens L, Yoga Y, Taiaroa G, Stefanatos H, Savic I, Tran T,
432 Deerain J, Prestedge J, Druce J, Caly L, Williamson DA. 2022. Analytical Sensitivity of Lateral Flow
433 Devices against SARS-CoV-2 Omicron Subvariants BA.4, BA.5, and BA.2.75. *J Clin Microbiol*
434 60:e0109722.
- 435 41. Jungnick S, Hobmaier B, Paravinja N, Mautner L, Hoyos M, Konrad R, Haase M, Baiker A, Eberle
436 U, Bichler M, Treis B, Okeyo M, Streibl B, Wimmer C, Hepner S, Sprenger A, Berger C, Weise L,
437 Dangel A, Ippisch S, Jonas W, Wildner M, Liebl B, Ackermann N, Sing A, Fingerle V, Bavarian S-C-
438 PHLT. 2023. Analysis of seven SARS-CoV-2 rapid antigen tests in detecting omicron (B.1.1.529)
439 versus delta (B.1.617.2) using cell culture supernatants and clinical specimens. *Infection* 51:239-
440 245.
- 441 42. Deerain J, Druce J, Tran T, Batty M, Yoga Y, Fennell M, Dwyer DE, Kok J, Williamson DA. 2022.
442 Assessment of the Analytical Sensitivity of 10 Lateral Flow Devices against the SARS-CoV-2
443 Omicron Variant. *J Clin Microbiol* 60:e0247921.

444